$UBX
Unity Biotechnology, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022029209 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $236.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.922M $4.941M $5.806M
YoY Change -14.36% -17.37% -6.75%
% of Gross Profit
Research & Development $8.208M $7.553M $12.46M
YoY Change -9.61% -31.44% 42.95%
% of Gross Profit
Depreciation & Amortization $535.0K $609.0K $627.0K
YoY Change -24.44% -18.15% -17.17%
% of Gross Profit
Operating Expenses $13.13M $12.49M $18.27M
YoY Change -11.45% -26.49% 22.24%
Operating Profit -$13.13M -$12.26M -$18.27M
YoY Change -11.45% -27.88% 22.24%
Interest Expense $866.0K $894.0K $808.0K
YoY Change -212.18% 14.03% 4.26%
% of Operating Profit
Other Income/Expense, Net -$41.00K -$43.00K $131.0K
YoY Change -95.18% -40.28% -277.03%
Pretax Income -$13.71M -$13.14M -$18.92M
YoY Change -16.67% -26.3% 20.05%
Income Tax
% Of Pretax Income
Net Earnings -$13.71M -$13.14M -$18.92M
YoY Change -16.67% -26.3% 20.05%
Net Earnings / Revenue -5566.53%
Basic Earnings Per Share -$1.36 -$0.19 -$2.80
Diluted Earnings Per Share -$1.36 -$0.19 -$280.1K
COMMON SHARES
Basic Shares Outstanding 69.65M 69.25M 6.753M
Diluted Shares Outstanding 10.07M 69.25M 6.753M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.94M $64.51M $79.16M
YoY Change 22.2% -23.15% -21.2%
Cash & Equivalents $22.58M $19.44M $16.45M
Short-Term Investments $76.36M $45.07M $62.72M
Other Short-Term Assets $3.784M $3.315M $2.320M
YoY Change 0.67% -9.55% 46.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.7M $67.82M $81.48M
YoY Change 21.24% -22.58% -20.15%
LONG-TERM ASSETS
Property, Plant & Equipment $8.202M $8.697M $30.01M
YoY Change -74.74% -74.17% 151.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.980M $0.00 $0.00
YoY Change -33.6% -100.0% -100.0%
Other Assets $76.00K $62.00K $972.0K
YoY Change -92.41% -95.71% -32.78%
Total Long-Term Assets $33.67M $29.77M $30.99M
YoY Change -17.81% -38.81% -32.85%
TOTAL ASSETS
Total Short-Term Assets $102.7M $67.82M $81.48M
Total Long-Term Assets $33.67M $29.77M $30.99M
Total Assets $136.4M $97.59M $112.5M
YoY Change 8.51% -28.38% -24.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.444M $1.437M $3.323M
YoY Change 37.85% -24.29% 68.25%
Accrued Expenses $4.593M $4.604M $9.529M
YoY Change -55.23% -59.95% 47.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.776M $7.087M $4.837M
YoY Change 617.04%
Total Short-Term Liabilities $16.77M $16.42M $17.91M
YoY Change 29.26% 22.58% 74.36%
LONG-TERM LIABILITIES
Long-Term Debt $13.26M $12.67M $14.53M
YoY Change -45.07% -49.1% -41.16%
Other Long-Term Liabilities $0.00 $0.00 $29.34M
YoY Change -100.0% -100.0% -11.8%
Total Long-Term Liabilities $13.26M $12.67M $14.53M
YoY Change -45.07% 54986.96% -41.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.77M $16.42M $17.91M
Total Long-Term Liabilities $13.26M $12.67M $14.53M
Total Liabilities $57.83M $57.66M $61.78M
YoY Change -14.9% -18.03% -9.46%
SHAREHOLDERS EQUITY
Retained Earnings -$445.8M -$432.1M -$418.9M
YoY Change 14.51% 15.88% 17.97%
Common Stock $524.6M $472.2M
YoY Change 17.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.57M $39.93M $50.69M
YoY Change
Total Liabilities & Shareholders Equity $136.4M $97.59M $112.5M
YoY Change 8.51% -28.38% -24.1%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$13.71M -$13.14M -$18.92M
YoY Change -16.67% -26.3% 20.05%
Depreciation, Depletion And Amortization $535.0K $609.0K $627.0K
YoY Change -24.44% -18.15% -17.17%
Cash From Operating Activities -$10.86M -$14.84M -$15.00M
YoY Change -6.06% 10.84% -0.66%
INVESTING ACTIVITIES
Capital Expenditures -$48.00K -$11.00K $0.00
YoY Change -51.02% -85.53% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$36.18M $17.70M -$5.817M
YoY Change -309.75% -2060.58% -141.33%
Cash From Investing Activities -$36.23M $17.69M -$5.817M
YoY Change -311.23% -1907.25% -141.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.22M 138.0K 4.330M
YoY Change 1631.72% -86.46% -56.98%
NET CHANGE
Cash From Operating Activities -10.86M -14.84M -15.00M
Cash From Investing Activities -36.23M 17.69M -5.817M
Cash From Financing Activities 50.22M 138.0K 4.330M
Net Change In Cash 3.134M 2.996M -16.46M
YoY Change -63.11% -122.45% -282.17%
FREE CASH FLOW
Cash From Operating Activities -$10.86M -$14.84M -$15.00M
Capital Expenditures -$48.00K -$11.00K $0.00
Free Cash Flow -$10.81M -$14.82M -$15.00M
YoY Change -5.67% 11.39% -0.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001463361
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38470
dei Entity Address Address Line1
EntityAddressAddressLine1
285 East Grand Ave.
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
45065000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
550000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q2 us-gaap Assets Current
AssetsCurrent
67822000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
90504000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9942000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4028000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30094000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7553000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20014000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19733000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10747000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12206000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12494000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
16996000
us-gaap Operating Expenses
OperatingExpenses
31939000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31939000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
58000
CY2022Q2 us-gaap Interest Expense
InterestExpense
894000
CY2021Q2 us-gaap Interest Expense
InterestExpense
784000
us-gaap Interest Expense
InterestExpense
1559000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-146000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-11000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13148000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69247818
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69247818
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54859727
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54859727
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68392934
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68392934
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54516445
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54516445
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2660000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-132000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18915000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50691000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
125000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2250000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-11000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
39931000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
82880000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2744000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15756000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
79953000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
612000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2782000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-10000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17826000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
65917000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
196000
CY2021Q2 ubx Repayment Of Promissory Note From Related Party From Purchase Of Common Stock
RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock
210000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
us-gaap Net Income Loss
NetIncomeLoss
-33582000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1236000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1501000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
708000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
384000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-603000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
151000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
ubx Non Cash Rent Expenses
NonCashRentExpenses
-1263000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-1124000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
886000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
498000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-29000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-541000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-696000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-737000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2742000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1069000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2130000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-23000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
23000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29807000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21526000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
163000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11876000
ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
0
ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
1784000
us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
0
us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
210000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
125000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
196000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4468000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11083000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13463000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4309000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20888000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14944000
us-gaap Interest Paid Net
InterestPaidNet
1014000
us-gaap Interest Paid Net
InterestPaidNet
1182000
ubx Issuance Of Common Stock In Payment Of Debt
IssuanceOfCommonStockInPaymentOfDebt
3178000
ubx Issuance Of Common Stock In Payment Of Debt
IssuanceOfCommonStockInPaymentOfDebt
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19442000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13498000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1446000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
1446000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20888000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14944000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-432100000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-400000000.0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13100000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17800000
us-gaap Net Income Loss
NetIncomeLoss
-32100000
us-gaap Net Income Loss
NetIncomeLoss
-33600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28500000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q2 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
64500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability, the fair value of right-of-use assets and lease liabilities, derivative liabilities related to debt and stock-based compensation. Actual results could differ from such estimates or assumptions.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
58716000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
187000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58529000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
78628000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
78584000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
ubx Compound Library And Option Agreement Execution Month And Year
CompoundLibraryAndOptionAgreementExecutionMonthAndYear
2016-02
ubx Compound Library And Option Agreement Expiration Month And Year
CompoundLibraryAndOptionAgreementExpirationMonthAndYear
2020-02
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1073000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1091000
us-gaap Operating Lease Cost
OperatingLeaseCost
2151000
us-gaap Operating Lease Cost
OperatingLeaseCost
2187000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
411000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
387000
us-gaap Variable Lease Cost
VariableLeaseCost
707000
us-gaap Variable Lease Cost
VariableLeaseCost
853000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
966000
CY2021Q2 us-gaap Sublease Income
SubleaseIncome
390000
us-gaap Sublease Income
SubleaseIncome
2014000
us-gaap Sublease Income
SubleaseIncome
535000
CY2022Q2 us-gaap Lease Cost
LeaseCost
518000
CY2021Q2 us-gaap Lease Cost
LeaseCost
1088000
us-gaap Lease Cost
LeaseCost
844000
us-gaap Lease Cost
LeaseCost
2505000
us-gaap Operating Lease Payments
OperatingLeasePayments
3416000
us-gaap Operating Lease Payments
OperatingLeasePayments
3313000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11729522
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2867000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4810000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4964000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5123000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5287000
CY2022Q2 ubx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16893000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39944000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7908000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
32036000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3463000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28573000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3029000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9787000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7184000
CY2022Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2022Q2 ubx Term Fee Due At Maturity Amount
TermFeeDueAtMaturityAmount
1563000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
21563000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1806000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
19757000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
7087000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12670000
CY2019Q2 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000.0
CY2022Q1 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
125000000.0
CY2022Q1 ubx Restructuring And Related Activities Initiation Month And Year
RestructuringAndRelatedActivitiesInitiationMonthAndYear
2022-02
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
30
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
us-gaap Severance Costs1
SeveranceCosts1
1900000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
800000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8666955
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2129140
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1293176
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9502919
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
200000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2250000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2782000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4910000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5526000
CY2022Q2 ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
0
ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
0
CY2021Q2 ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
0
ubx Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17826000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
us-gaap Net Income Loss
NetIncomeLoss
-33582000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69247818
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69247818
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54859727
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54859727
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68392934
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68392934
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54516445
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54516445
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11353999
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Registrant Name
EntityRegistrantName
Unity Biotechnology, Inc.
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
UBX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei City Area Code
CityAreaCode
650
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12670000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
18409000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000
CY2022Q2 us-gaap Liabilities
Liabilities
57662000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4726035
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69651035
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
55170000
CY2021Q4 us-gaap Liabilities
Liabilities
65143000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Local Phone Number
LocalPhoneNumber
416-1192
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2765000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8697000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28573000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4604000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6370000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
216000
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
963000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
7087000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3055000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16419000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16617000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69584933
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69584933
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62991906
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62991906
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
472187000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
459631000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-187000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-432076000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-400024000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19442000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32905000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
26000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
87000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
550000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20116000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21286000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1993000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91000
CY2022Q2 us-gaap Assets
Assets
97593000
CY2021Q4 us-gaap Assets
Assets
124712000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1437000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1985000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3291000
us-gaap Operating Expenses
OperatingExpenses
30761000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16996000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30525000
us-gaap Interest Expense
InterestExpense
1702000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
88000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17826000
us-gaap Net Income Loss
NetIncomeLoss
-33582000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-10000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-143000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17836000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32195000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33582000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
39931000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97593000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124712000
us-gaap Share Based Compensation
ShareBasedCompensation
4910000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11016000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4941000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5980000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
62000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
us-gaap Share Based Compensation
ShareBasedCompensation
5526000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
62000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13083000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19253000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.44
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-231000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28475000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
56577000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
69750000

Files In Submission

Name View Source Status
0001564590-22-029209-index-headers.html Edgar Link pending
0001564590-22-029209-index.html Edgar Link pending
0001564590-22-029209.txt Edgar Link pending
0001564590-22-029209-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-10q_20220630.htm Edgar Link pending
ubx-20220630.xsd Edgar Link pending
ubx-ex311_7.htm Edgar Link pending
ubx-ex312_6.htm Edgar Link pending
ubx-ex321_8.htm Edgar Link pending
ubx-20220630_cal.xml Edgar Link unprocessable
ubx-20220630_def.xml Edgar Link unprocessable
ubx-20220630_lab.xml Edgar Link unprocessable
ubx-20220630_pre.xml Edgar Link unprocessable
ubx-10q_20220630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable